The MedLift Study was conducted to validate the safety and efficacy of the UroLift System treatment.
Findings showed significant improvements in international prostate symptom score (IPSS), peak flow rate (Qmax) and quality of life (QoL).
Mean IPSS was found to have improved by at least 13.5 points from baseline, while mean Qmax improvement ranged from 90% to 129% and QoL improvements were seen at three, six and 12 months.
Outcomes were found to be consistent with those of the five-year pivotal L.I.F.T study of UroLift.
These latest results were published in the Nature Publishing Group’s Prostate Cancer and Prostatic Diseases journal.
The data also supported the recent US Food and Drug Administration (FDA) clearance allowing UroLift System treatment for BPH symptoms in patients with an obstructive median lobe.
Teleflex Interventional Urology business unit president Dave Amerson said: “The MedLift Study provides additional evidence of the UroLift System’s utility for the treatment of a broad range of men with BPH, allowing more patients to benefit from this minimally invasive technology.
“The data from this study, among the many supportive findings from a number of clinical and real-world studies of the UroLift System, have helped the UroLift System become a standard of care treatment for patients with BPH.”
Teleflex acquired NeoTract in 2017 for approximately $1.1bn. NeoTract’s UroLift System is a minimally invasive technology indicated for lower urinary tract symptoms caused due to BPH.
The device is permanently implanted during a minimally invasive transurethral outpatient procedure.